Erythropoietin increases macrophage-mediated T cell suppression

Cellular Immunology

Volumn 306-307, Issue , 2016, Pages 17-24

  Wood, Michelle A ^a   Goldman, Naomi ^a   DePierri, Kelley ^a   Somerville, John ^a   Riggs, James E ^a  

^a RIDER UNIVERSITY   (United States)

Author keywords

EPO; EPOR; iNOS; Macrophage; Tumor microenvironment

Indexed keywords

CD11B ANTIGEN; ERYTHROPOIETIN; GAMMA INTERFERON RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SUPEROXIDE; THYMIDINE; ERYTHROPOIETIN RECEPTOR; INTERFERON RECEPTOR; NOS2 PROTEIN, MOUSE;

AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASSAY; CATABOLISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC VARIATION; HEMATOLOGICAL PARAMETERS; LIGATION; LYMPHOCYTE; MACROPHAGE TO LYMPHOCYTE RATIO; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEUM CELL; PERITONEUM MACROPHAGE; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TETRAZOLIUM DYE ASSAY; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD11B; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNE TOLERANCE; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; PERITONEAL CAVITY; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, INTERFERON; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84973882712     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2016.05.004     Document Type: Article

References (65)

1. [1] Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases – elimination, equilibrium, escape. Curr. Opin. Immunol. 27 (2014), 16–25.
2. [2] Murdoch, C., Muthana, M., Coffelt, S.B., Lewis, C.E., The role of myeloid cells in the promotion of tumor angiogenesis. Nat. Rev. Cancer 8 (2008), 618–631.
3. [3] Coffelt, S.B., Hughes, R., Lewis, C.E., Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 1796 (2009), 11–18.
4. [4] Horowitz, J.R., Rivard, A., van der Zee, R., Hariawala, M., Sheriff, D.D., Esakof, D.D., Chaudhry, G.M., Symes, J.F., Isner, J.M., Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol 17 (1997), 2793–2800.
5. [5] Dvorak, H.F., Tumors: wounds that do not heal-redux. Cancer Immunol. Res. 315 (2015), 1650–1659.
6. [6] Dirkx, A.E., Oude Egbrink, M.G., Wagstaff, J., Griffioen, A.W., Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 80 (2006), 1183–1196.
7. [7] Ruffell, B., Couesens, L.M., Macrophages and therapeutic resistance in cancer. Cancer Cell 27 (2015), 462–472.
8. [8] Cotechini, T., Medler, T.R., Couessens, L.M., Myeloid cells as targets for therapy in solid tumors. J. Cancer 4 (2015), 343–350.
9. [9] Ellis, L.M., Hicklin, D.J., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8 (2008), 579–591.
10. [10] Kelly, P.M., Davison, R.S., Bliss, E., McGee, J.O., Macrophages in human breast disease: a quantitative immunohistochemical study. Br. J. Cancer 57 (1988), 174–177.
11. [11] Mills, C.D., Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit. Rev. Immunol. 21 (2001), 399–425.
12. [12] Pollard, J.W., J, Tumor-educated macrophages promote tumor progression and metastasis. Nat. Rev. Cancer 4 (2004), 71–78.
13. [13] Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J.I., Cheresh, D.A., Johnson, R.S., Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456 (2008), 814–818.
14. [14] De Maria, R., Testa, U., Luchetti, L., Zeuner, A., Stassi, G., Pelosi, E., Riccioni, R., Felli, N., Samoggia, P., Peschle, C., Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 93 (1999), 796–803.
15. [15] Liu, Y., Pop, R., Sadegh, C., Brugnara, C., Haas, V.H., Socolovsky, M., Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 108 (2006), 123–133.
16. [16] Nairz, M., Schroll, A., Moschen, A.R., Sonnweber, T., Theurl, M., Theurl, I., Taub, N., Jamnig, C., Neurauter, D., Huber, L.A., Tilg, H., Moser, P.L., Weiss, G., Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-k-B-inducible immune pathways. Immunity 34 (2011), 61–74.
17. [17] Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 316 (1987), 73–78.
18. [18] Crawford, J., Erythropoietin: high profile, high security. J. Clin. Oncol. 25 (2007), 1021–1023.
19. [19] Sytkowski, A.J., Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci. STKE, 395, 2007 pe38.
20. [20] Broxmeyer, H.E., Erythropoietin surprises: an immune saga. Immunity 34 (2011), 6–7.
21. [21] Dicato, M., Plawny, L., Erythropoietin in cancer patients: pros and cons. Curr. Opin. Oncol. 22 (2010), 307–311.
22. [22] Glaspy, J., Crawford, J., Vansteenkiste, J., Henry, D., Rao, S., Bowers, P., Berlin, J.A., Tomita, D., Bridges, K., Ludwig, H., Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 102 (2010), 301–315.
23. [23] Rizzo, J.D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M.O., Spivak, J.L., Bennett, C.L., Bohlius, J., Evanchuk, D., Goode, M.J., Jakubowski, A.A., Regan, D.H., Somerfield, M.R., American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116 (2010), 4045–4059.
24. [24] Ribatti, D., Erythropoietin and tumor angiogenesis. Stem Cells Dev. 19 (2010), 1–4.
25. [25] Ohm, J.E., Carbone, D.P., VEGF as a mediator of tumor–associated immunodeficiency. Immunol. Res., 23, 2001, 263.
26. [26] Brines, M., Cerami, A., Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J. Intern. Med. 264 (2008), 405–432.
27. [27] Acs, G., Acs, P., Beckwith, S.M., Pitts, R.L., Clements, E., Wong, K., Verma, A., Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61 (2001), 3561–3565.
28. [28] Jeong, J.Y., Feldman, L., Solar, P., Szenajch, J., Sytkowski, A.J., Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int. J. Cancer 122 (2008), 274–280.
29. [29] Elliott, S., Busse, L., McCaffery, I., Rossi, J., Sinclair, A., Spahr, C., Swift, S., Begley, C.G., Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J. Immunol. Methods 352 (2009), 126–139.
30. [30] Elliott, S., Sinclair, A., Collins, H., Rice, L., Jelkmann, W., Progress in detecting cell-surface protein receptors: the erythropoietin receptor example. Ann. Hematol. 93 (2014), 181–192.
31. [31] Paragh, G., Kumar, S.M., Rakosy, Z., Choi, S.C., Xu, X., Acs, G., RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 ovarian carcinoma cells. Am. J. Pathol. 174 (2009), 1504–1514.
32. [32] Jelkmann, W., Erythropoietin: back to basics. Blood 115 (2010), 4151–4152.
33. [33] Sinclair, A.M., Coxon, A., McCaffery, I., Kaufman, S., Paweletz, K., Liu, L., Busse, L., Swift, S., Elliott, S., Begley, C.G., Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115 (2010), 4264–4272.
34. [34] Swift, S., Ellison, A.R., Kassner, P., McCaffery, I., Rossi, J., Sinclair, A.M., Begley, C.G., Elliott, S., Absence of functional EpoR expression in human tumor cell lines. Blood 115 (2010), 4254–4263.
35. [35] Maxwell, P., Melendez-Rodriguez, F., Matchett, K.B., Aragones, J., Ben-Califa, N., Jaekel, H., Hengst, L., Lindner, H., Bernardini, A., Brockmeier, U., Fandrey, J., Grunert, F., Oster, H.S., Mittelman, M., El-Tanani, M., Thiersch, M., Schneider Gasser, E.M., Gasserman, M., Dangoor, D., Cuthbert, R.J., Irvine, A., Jordan, A., Lappin, T., Thompson, J., Neumann, D., Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation. Br. J. Haematol. 168 (2015), 429–442.
36. [36] Prutchi Sagiv, S., Lifshitz, L., Orkin, R., Mittelman, M., Neumann, D., Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?. Exp. Hematol. 36 (2008), 1682–1690.
37. [37] Lifshitz, L., Prutchi Sagiv, S., Avneon, M., Gassmann, M., Mittelman, M., Neumann, D., Non-erythroid activities of erythropoietin: functional effects on murine dendritic cells. Mol. Immunol. 46 (2010), 713–721.
38. [38] Lifshitz, L., Tabak, G., Gassmann, M., Mittelman, M., Neumann, D., Macrophages as novel targets for erythropoietin. Haematologica 95 (2010), 1823–1831.
39. [39] Lisowska, K., Debska-Slizien, A., Bryl, E., Rutkowski, B., Witkowski, J., Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. Artif. Organs 34 (2010), 654–662.
40. [40] Lisowska, K., Bryl, E., Witkowski, J., Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes. Haematologica 96 (2011), e12–e13.
41. [41] Matlack, R., Yeh, K., Rosini, L., Gonzalez, D., Taylor, J., Silberman, D., Pennello, A., Riggs, J., Peritoneal macrophages suppress T-cell activation by amino acid catabolism. Immunology 117 (2006), 386–395.
42. [42] Composto, G., Gonzalez, D., Bucknum, A., Silberman, D., Taylor, J., Kozlowski, M., Bloomfield, T., Bartlett, T., Riggs, J., Peritoneal T lymphocyte regulation by macrophages. Immunobiology 216 (2011), 256–264.
43. [43] Silberman, D., Bucknum, A., Kozlowski, M., Matlack, R., Riggs, J., Cytokine treatment of macrophage suppression of T cell activation. Immunobiology 215 (2010), 70–80.
44. [44] Silberman, D., Bucknum, A., Bartlett, T., Composto, G., Kozlowski, M., Walker, A., Werda, A., Cua, J., Sharpe, A.H., Somerville, J.E., Riggs, J., CD28 ligation increases macrophage suppression of T-cell proliferation. Cell. Mol. Immunol. 9 (2012), 341–349.
45. [45] Motz, G.T., Coukos, G., The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11 (2011), 702–711.
46. [46] Grohmann, U., Fallarino, F., Puccetti, P., Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24 (2003), 242–248.
47. [47] Rocchetta, F., Solini, S., Mister, M., Mele, C., Cassis, P., Noris, M., Remuzzi, G., Aiello, S., Erythropoietin enhances immunostimulatory properties of immature dendritic cells. Clin. Exp. Immunol. 165 (2011), 202–210.
48. [48] Cravedi, P., Manrique, J., Hanlon, K.E., Reid-Adam, J., Brody, J., Prathuangsuk, P., Mehrotra, A., Heeger, P.S., Immunosuppressive effects of erythropoietin on human alloreactive T cells. J. Am. Soc. Nephrol. 25 (2014), 2003–2015.
49. [49] Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., Coffman, R.L., Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J. Immunol. 175 (2005), 5–14.
50. [50] Tan, A.S., Berridge, M.V., Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J. Immunol. Methods 238 (2000), 59–68.
51. [51] Berridge, M.V., Herst, P.M., Tan, A.S., Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol. Annu. Rev. 11 (2005), 127–152.
52. [52] Haroon, Z.A., Amin, K., Jiang, X., Arcasoy, M.O., A novel role for erythropoietin during fibrin-induced wound-healing response. Am. J. Pathol. 163 (2003), 993–1000.
53. [53] Nairz, M., Sonnweber, T., Schroll, A., Theurl, I., Weiss, G., The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. 14 (2012), 238–246.
54. [54] Sautina, L., Sautin, Y., Beem, E., Zhou, Z., Schuler, A., Brennan, J., Zharikov, S., Diao, Y., Bungert, J., Segal, M., Induction of nitric oxide by erythropoietin is mediated by the beta common receptor and requires interaction with the VEGF receptor 2. Blood 115 (2010), 896–905.
55. [55] Beleslin-Cokic, B.B., Cokic, V.P., Wang, L., Piknova, B., Teng, R., Schechter, A.N., Noguchi, C.T., Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells. Cytokine 54 (2011), 129–135.
56. [56] Biswas, S.K., Sica, A., Lewis, C.E., Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 180 (2008), 2011–2017.
57. [57] Huang, L.J., Constantinescu, S.N., Lodish, H.F., The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell 8 (2001), 1327–1338.
58. [58] Jubinsky, P.T., Krijanovski, O.I., Nathan, D.G., Tavernier, J., Sieff, C.A., The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997:90 (1997), 1867–1873.
59. [59] Broxmeyer, H.E., Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J. Exp. Med. 210 (2013), 205–208.
60. [60] Jelkman, W., Regulation of erythropoietin production. J. Physiol. 589 (2011), 1251–1258.
61. [61] Owen, W.E., Roberts, W.L., Performance characteristics of a new Immulite (®) 2000 system erythropoietin assay System erythropoietin assay. Clin. Chim. Acta 412:2011 (2000), 480–482.
62. [62] < http://assets.procrit.com/shared/product/procrit/procrit-prescribing-information.pdf>.
63. [63] Lee, A.S., Kim, D.H., Lee, J.E., Jung, Y.J., Kang, K.P., Lee, S., Park, S.K., Kwak, J.Y., Lee, S.Y., Lim, S.T., Sung, M.J., Yoon, S.R., Kim, W., Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res. 71 (2011), 4506–4517.
64. [64] Okazaki, T., Ebihara, S., Asada, M., Yamanda, S., Niu, K., Arai, H., Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10 (2008), 932–939.
65. [65] Yoshioka, K., Thompson, J., Miller, M.J., Fisher, J.W., Inducible nitric oxide synthase expression and erythropoietin production in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 232 (1997), 702–706.